I'm LongbridgeAI, I can summarize articles.Oculis reported a narrowed net loss of CHF 38.82 million for H1 FY26, down from CHF 58.59 million previously. Operating losses widened to CHF 45.3 million, while finance results improved significantly. Cash reserves stood at $282.3 million, supporting operations into late 2029. Clinically, PIONEER-1 site activations advanced, and FDA feedback indicated no additional preclinical work is needed for the acute MS relapse IND, targeted for Q4 2026.
- Oculis posted a net loss of CHF 38.82 million for the six months ended June 30, narrowing from CHF 58.59 million a year earlier. * Operating loss widened to CHF 45.3 million from CHF 40.74 million, while finance result swung to CHF 6.38 million from a loss of CHF 17.86 million. * R&D expenses edged up to CHF 29.33 million from CHF 29.68 million; G&A costs rose to CHF 16.49 million from CHF 11.61 million. * Cash, cash equivalents and short-term investments totaled $282.3 million at June 30, supporting runway into 2H 2029. * PIONEER-1 Privosegtor site activations advanced; FDA feedback cleared no added preclinical work for acute MS relapse IND, targeted for Q4 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oculis Holding AG published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here